Market Outlook

By 2035, the U.S. Cancer Treatment Devices Market is expected to reach approximately USD 36.81 billion, expanding at a CAGR of 10.80% during the forecast period 2026–2035. The market is estimated at USD 13.20 billion in 2025, with historical analysis covering 2021–2024. Values throughout this report are expressed in USD billions.

The historical market increased from approximately USD 9.15 billion in 2021 to USD 11.95 billion in 2024, before reaching USD 13.20 billion in 2025. The estimated trajectory is USD 9.15 billion in 2021, USD 9.83 billion in 2022, USD 10.73 billion in 2023, USD 11.95 billion in 2024, and USD 13.20 billion in 2025. Based on the forecast model, revenue is expected to rise to approximately USD 14.63 billion in 2026, USD 22.04 billion by 2030, and USD 36.81 billion by 2035.

The U.S. cancer treatment devices industry represents a strategically important intersection of radiation oncology, surgical oncology, interventional oncology, tumor ablation, image-guided treatment, robotic intervention, and emerging field-based or non-thermal tumor destruction technologies. Demand is underpinned by a cancer burden exceeding 2 million newly diagnosed cases annually, an aging population, longer cancer survivorship, increasing numbers of patients receiving multimodality treatment, and continued movement toward less invasive and more precisely targeted procedures.

This report defines cancer treatment devices as equipment, systems, treatment-specific disposables, procedural platforms, treatment-planning technologies, and energy-delivery technologies whose primary purpose is the physical treatment or destruction of malignant tissue. The scope includes external beam radiation therapy systems, radiosurgery platforms, proton therapy equipment, brachytherapy systems, tumor ablation technologies, histotripsy, interventional oncology treatment devices, tumor treating fields, and oncology-directed robotic or image-guided treatment platforms. Diagnostic imaging, screening systems, biopsy devices, pharmaceutical cancer therapeutics, radiopharmaceutical products themselves, laboratory diagnostics, and general-purpose hospital equipment are excluded unless directly integrated into a cancer-treatment procedure.

Cancer treatment device procurement is increasingly driven by the economics of the complete care episode rather than equipment specifications alone. U.S. health systems are evaluating capital purchases according to patient throughput, treatment-room utilization, procedure duration, staffing intensity, reimbursement capture, service-contract requirements, consumable pull-through, treatment planning time, downtime risk, and the ability to shift suitable procedures from inpatient surgery toward outpatient or short-stay care.

Radiation oncology remains the largest treatment-device value pool, while tumor ablation, non-thermal tumor destruction, biology-guided radiation treatment, tumor treating fields, advanced stereotactic treatment, and robotics-supported oncologic procedures are expected to generate disproportionate incremental growth through 2035.

 

Introduction

According to the U.S. Cancer Treatment Devices Market Report, the market is positioned for sustained premium growth because the United States combines a large cancer population with highly developed oncology infrastructure, substantial Medicare and commercial payer expenditure, concentrated clinical expertise, advanced hospital capital budgets, and one of the world’s most active medical device innovation ecosystems.

Approximately 2.04 million new cancer cases were expected in the United States in 2025, equivalent to roughly 5,600 new diagnoses each day. Breast cancer, prostate cancer, lung cancer, colorectal cancer, melanoma, hematologic malignancies, and cancers of the urinary and reproductive systems collectively create a broad and recurring treatment pool. The economic implications are substantial: U.S. cancer care expenditures were already estimated above USD 200 billion annually in earlier national expenditure assessments, and costs continue to face upward pressure from aging demographics, longer survival, technological sophistication, and increasing treatment intensity.

Physical device-based treatment remains fundamental despite extraordinary progress in immunotherapy, targeted therapies, and precision medicines. Radiation therapy is used during the care pathway for roughly half of cancer patients, while surgery remains central to curative treatment for many solid tumors. Interventional oncology has expanded the addressable population for patients who require localized treatment but may not be appropriate candidates for conventional surgery.

The U.S. treatment infrastructure also creates unusually favorable conditions for adoption of premium oncology equipment. Academic hospitals and comprehensive cancer programs function as early evaluators of adaptive radiotherapy, stereotactic systems, proton therapy, biology-guided treatment, advanced ablation, histotripsy, robotic surgery, and treatment-planning software. In fiscal 2025, the National Cancer Institute supported 73 P30-designated cancer-center core grants, demonstrating the scale of the country’s advanced cancer research and treatment ecosystem.

Unlike pharmaceutical oncology, however, the device market is constrained by capital cycles. A health system may use a radiation platform for many years, making replacement demand dependent on installed-base age, service costs, software compatibility, clinical obsolescence, and whether new technology creates sufficient incremental throughput or reimbursement value. Vendors therefore compete not only on clinical performance but on lifecycle economics.

The next decade will increasingly favor platforms that combine treatment precision, imaging, planning, automation, workflow analytics, remote service, AI-assisted decision support, and predictable clinical throughput. Equipment manufacturers able to prove that technology improves capacity utilization and clinical outcomes simultaneously will have a stronger procurement position than manufacturers relying exclusively on technical specifications.

 

Key Market Drivers: What’s Fueling the U.S. Cancer Treatment Devices Market Boom?

The first major growth driver is the absolute scale of U.S. cancer incidence. Approximately 2.04 million new cancer cases were projected during 2025, including approximately 316,950 female breast cancer cases, 313,780 prostate cancer cases, 226,650 lung and bronchus cancer cases, and 154,270 colorectal cancer cases. These four disease areas alone support substantial demand for radiation therapy, surgery, radiosurgery, brachytherapy, thermal ablation, image-guided procedures, and interventional oncology.

The second driver is the expansion of precision radiation oncology. Radiation therapy remains one of the fundamental treatment modalities in cancer care, but the technology mix is moving from conventional fractionated radiotherapy toward IMRT, image-guided radiation therapy, stereotactic body radiation therapy, stereotactic radiosurgery, adaptive radiotherapy, motion management, proton therapy, and increasingly automated treatment planning. The economic effect is important because premium systems carry substantially higher capital and service value while software upgrades and planning tools extend recurring revenue beyond the original hardware purchase.

The third driver is hypofractionation and higher treatment throughput. Delivering effective treatment in fewer fractions can reduce patient travel and treatment burden while allowing oncology centers to use installed radiation equipment more efficiently. This creates a nuanced commercial environment. Fewer fractions can lower the number of billable treatment sessions per patient, but higher throughput can allow providers to treat additional patients using the same treatment room. Consequently, vendors are increasingly selling productivity and capacity expansion rather than simply beam-delivery capability.

The fourth driver is the rapid development of minimally invasive interventional oncology. Microwave ablation, radiofrequency ablation, cryoablation, irreversible electroporation, focused ultrasound, histotripsy, embolization, and image-guided catheter-based therapies provide options for localized treatment of liver, kidney, lung, bone, prostate, and other tumors. These approaches are particularly attractive when patients are medically fragile, have recurrent disease, or require local control without major open surgery.

The U.S. tumor ablation market alone represented a substantial sub-billion-dollar opportunity in 2025 and is growing considerably faster than many mature surgical-device categories. As interventional radiologists and multidisciplinary oncology teams expand their treatment roles, procedure volumes are expected to migrate toward higher-value disposable probes, generators, navigation technologies, and treatment-planning ecosystems.

The fifth driver is the growth of robotic and image-guided oncologic surgery. Prostatectomy, partial nephrectomy, hysterectomy, colorectal resection, thoracic surgery, and selected head-and-neck procedures increasingly use minimally invasive robotic workflows. For hospitals, robotic oncology is strategically attractive because it can combine specialist recruitment, premium procedure capture, shorter hospitalization, reduced surgical trauma, and operating-room differentiation. Competitive advantage increasingly depends on instrument ecosystems, imaging integration, visualization, training, utilization management, and procedure-specific clinical capabilities rather than the robotic platform alone.

The sixth driver is the emergence of non-traditional physical cancer treatment technologies. Tumor treating fields provide a portable, non-invasive treatment model based on alternating electrical fields, while histotripsy uses focused ultrasound to mechanically destroy targeted tissue without conventional thermal ablation. These technologies expand the definition of device-based oncology and create new revenue streams outside conventional radiation and surgery.

The seventh driver is hospital replacement and modernization cycles. Radiation oncology departments must manage aging linear accelerators, software compatibility, treatment-planning systems, cybersecurity, imaging upgrades, service availability, and emerging clinical requirements. Equipment that remains mechanically functional can still become economically obsolete when it cannot support modern adaptive workflows, shorter treatment protocols, advanced imaging, automation, or enterprise data integration.

The eighth driver is payer and health-system pressure to improve treatment economics. Medicare policy directly affects radiation oncology through the Physician Fee Schedule and hospital outpatient payment environment. In 2026, CMS incorporated routinely updated hospital outpatient data into rate-setting assumptions for certain radiation treatment services, reinforcing the need for manufacturers to understand provider economics rather than viewing reimbursement as separate from product strategy.

Finally, patient expectations are changing. Cancer patients increasingly seek shorter treatment courses, minimally invasive approaches, organ preservation, reduced recovery times, lower travel burden, and treatment closer to home. Technologies that deliver measurable clinical value while reducing logistical friction are therefore positioned to achieve disproportionately strong adoption.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. Cancer Treatment Devices Market is moving from equipment-centered competition toward intelligent treatment ecosystems. The strategic question is increasingly not whether a machine can deliver treatment, but whether the complete platform can identify anatomy, plan the procedure, adapt to change, deliver therapy accurately, document performance, reduce clinical workload, and generate evidence useful to hospital administrators and payers.

Adaptive radiation therapy is one of the most commercially important developments. Tumor position, organ filling, patient anatomy, and treatment response can change during a radiation course. Advanced imaging and planning technologies allow treatment plans to be modified closer to the treatment session rather than relying exclusively on the original planning scan. This creates opportunities for oncology vendors offering integrated imaging, contouring, dose calculation, workflow automation, and treatment delivery.

Artificial intelligence is also moving deeper into radiation oncology workflows. AI-supported segmentation and contouring can reduce repetitive planning work, automated treatment-plan generation can improve standardization, and secondary-check algorithms can support safety and quality assurance. FDA activity has already included multiple AI/ML-based applications for treatment planning, secondary checks, and automated contouring. The commercial implication is that software capability increasingly influences capital-platform competitiveness.

Biology-guided radiation therapy represents another important frontier. Rather than relying solely on anatomical positioning, biology-guided approaches can integrate functional signals associated with active tumors into the treatment process. The technology could become particularly valuable for complex metastatic disease, where identifying and treating multiple targets efficiently creates significant workflow challenges.

Proton therapy is also evolving. Historically, proton centers required extremely high capital investment, specialized construction, and large patient volumes. Compact systems, improved treatment-room design, seated treatment concepts, and advances in beam delivery are intended to improve accessibility and economics. The U.S. proton therapy market was already valued at approximately USD 1.1 billion in 2025 under broader market definitions, illustrating its importance as a premium oncology infrastructure category.

Stereotactic radiosurgery and stereotactic body radiation therapy continue to reshape treatment economics by enabling extremely precise high-dose treatment in limited fractions. Brain metastases, early-stage lung tumors, spine lesions, prostate cancer, oligometastatic disease, and selected liver tumors are important clinical opportunities. Vendors are therefore competing on image guidance, motion management, beam shaping, treatment time, patient positioning, planning automation, and clinical confidence.

Non-thermal tumor destruction is creating an additional innovation cycle. The FDA-authorized Edison System introduced histotripsy for non-invasive mechanical destruction of liver tumors, including unresectable tumors. Unlike conventional thermal ablation, histotripsy uses focused ultrasound to mechanically disrupt targeted tissue. The technology remains early in its commercialization curve but illustrates how physical tumor treatment is expanding beyond radiation, heat, freezing, and surgery.

Tumor treating fields are moving beyond their established role in glioblastoma. U.S. regulatory approvals have expanded the technology into metastatic non-small-cell lung cancer and, in 2026, locally advanced pancreatic cancer. Home-based treatment also changes the device business model because revenue is linked to longitudinal use rather than a single hospital procedure or capital purchase.

Interventional oncology manufacturers are innovating around better lesion access, ablation-zone predictability, navigation, probe design, embolic delivery, image fusion, temperature management, and procedure standardization. As interventions become technically reproducible and evidence improves, large health systems can establish dedicated interventional oncology programs rather than treating procedures as isolated radiology services.

Across all categories, manufacturers are also raising the bar through evidence generation. Capital committees increasingly expect clinical outcomes, complication data, comparative procedure time, throughput assumptions, staffing implications, service-cost projections, reimbursement scenarios, and real-world utilization evidence. A technically superior device without a compelling economic pathway can face slower adoption than a platform that solves both clinical and operational problems.

 

Segmentation Insights

The U.S. Cancer Treatment Devices Market is segmented on the basis of product category, treatment modality, cancer type, end user, and region.

 

By Product Category

External Beam Radiation Therapy, Radiosurgery and Particle Therapy Systems

External beam radiation therapy represents the largest product category. The segment includes linear accelerators, stereotactic radiosurgery platforms, stereotactic body radiation systems, proton therapy systems, treatment-planning software, patient-positioning technologies, motion-management equipment, and associated radiation oncology accessories. The category is estimated to account for approximately USD 5.25 billion of the 2025 treatment-device opportunity under this report’s scope.

Growth is increasingly tied to adaptive workflows, onboard imaging, shortened treatment courses, automated planning, stereotactic capability, and replacement of older installed systems. Purchasing decisions are heavily influenced by uptime, throughput, service infrastructure, software interoperability, room requirements, and the number of clinical indications a system can support.

Brachytherapy Systems and Applicators

Brachytherapy remains an established treatment modality for prostate, cervical, uterine, breast, and selected other malignancies. Products include afterloaders, applicators, needles, catheters, radioactive-seed delivery hardware, treatment-planning technology, and accessories.

The category is smaller than external beam radiation but remains clinically important because it can deliver highly localized radiation while limiting dose to surrounding tissue. HDR brachytherapy infrastructure is particularly important in gynecologic oncology and specialized radiation centers. Growth through 2035 will depend on procedural standardization, imaging integration, physician expertise, and preservation of brachytherapy capability within cancer centers.

Tumor Ablation and Histotripsy Devices

Tumor ablation is one of the fastest-expanding product categories and includes microwave ablation, radiofrequency ablation, cryoablation, irreversible electroporation, focused ultrasound, and non-thermal mechanical tissue-destruction systems.

The U.S. market benefits from growing use of minimally invasive treatment for liver, kidney, lung, bone, prostate, and metastatic lesions. Commercial economics are attractive because many platforms combine reusable capital equipment with high-value disposable probes or procedure-specific consumables. Histotripsy adds a new technology class and could expand the addressable market when clinical evidence, provider training, reimbursement, and site availability mature.

Interventional Oncology and Embolization Devices

Interventional oncology includes embolization devices, microcatheters, guidewires, delivery systems, particles, coils where used for oncologic procedures, radioembolization-support hardware, and other minimally invasive locoregional treatment technologies.

The segment is estimated to represent approximately USD 2.6 billion of U.S. treatment-device revenue in 2025 when appropriately scoped to oncology applications. Demand is supported by primary and metastatic liver tumors, complex unresectable disease, multidisciplinary tumor boards, and increasing acceptance of interventional radiology as an active treatment specialty rather than solely a diagnostic discipline.

Tumor Treating Fields and Oncology-Specific Robotic or Surgical Platforms

This category captures device-based treatment technologies outside traditional radiation and percutaneous ablation, including tumor treating fields, oncology-directed robotic treatment applications, specialized resection technologies, surgical energy systems allocated to cancer procedures, and related treatment consumables.

Robotic oncology is most economically significant in prostate, kidney, gynecologic, colorectal, and thoracic procedures. Tumor treating fields are smaller by absolute revenue but are expected to grow rapidly because of expanded indications and their recurring treatment model.

 

By Treatment Modality

Radiation-Based Local Treatment

Radiation-based treatment is the largest modality and includes conventional external beam therapy, IMRT, IGRT, stereotactic treatment, radiosurgery, proton therapy, and brachytherapy. Roughly half of cancer patients receive radiation during their treatment pathway, creating a large addressable clinical base.

The most important commercial transition is from radiation delivery as an isolated function toward integrated image-guided and adaptive treatment. Vendors able to combine planning, imaging, delivery, automation, motion management, and longitudinal software are positioned to capture a larger portion of oncology department expenditure.

Thermal Tumor Ablation

Microwave and radiofrequency ablation use thermal energy to destroy malignant tissue and are well established in interventional oncology. Microwave ablation is benefiting from faster energy delivery and the ability to create clinically useful ablation zones in selected tumors.

Growth is particularly attractive for liver, kidney, lung, and metastatic lesions where minimally invasive local treatment can reduce recovery compared with open surgery.

Cryoablation and Non-Thermal Tissue Destruction

Cryoablation provides controlled tissue freezing with visualizable treatment margins under appropriate imaging guidance. Irreversible electroporation and histotripsy expand the non-traditional local-treatment category.

These modalities are strategically important because they may address anatomy or patient populations poorly suited to conventional thermal approaches. Adoption will depend on comparative clinical evidence and the ability to demonstrate durable local tumor control.

Catheter-Based Locoregional Treatment

Transarterial and catheter-directed oncology procedures allow treatment to be delivered directly to tumors or their blood supply. Liver cancer and hepatic metastases represent the principal opportunity, although the broader field continues to evolve.

Hospitals increasingly assess these technologies as multidisciplinary oncology assets involving interventional radiology, medical oncology, radiation oncology, hepatology, and surgery. That multidisciplinary structure can create meaningful barriers to adoption but also improves vendor stickiness after programs are established.

Surgical, Robotic and Field-Based Treatment

Surgical excision remains a central curative treatment for many localized solid tumors. Robotic systems and advanced energy devices increasingly support minimally invasive cancer surgery, while tumor treating fields create a separate device-mediated therapy model that may be delivered outside conventional procedural environments.

The home-treatment component of tumor treating fields is particularly differentiated because it extends the device relationship beyond the hospital and creates recurring utilization economics.

 

By Cancer Type

Breast Cancer

Breast cancer is one of the largest cancer-treatment device opportunities in the United States, with approximately 316,950 female breast cancer cases estimated in 2025. Device demand spans breast-conserving surgery, radiation therapy, stereotactic treatment, intraoperative visualization, localization technologies, brachytherapy in selected patients, and advanced surgical systems.

Because survival is comparatively favorable for many stages, hospitals strongly emphasize toxicity reduction, cosmetic outcomes, treatment convenience, and long-term quality of life. Shorter radiation schedules and more precise planning are therefore commercially important.

Prostate Cancer

Approximately 313,780 new prostate cancer cases were estimated in 2025, making prostate cancer another major device-intensive category. Treatment may involve robotic prostatectomy, external beam radiation therapy, stereotactic radiation, brachytherapy, cryoablation, high-intensity focused ultrasound, and other focal technologies.

The market is moving toward risk-stratified treatment. Vendors must therefore address an environment where some low-risk patients undergo active surveillance while intermediate- and high-risk cases support substantial procedural demand.

Lung Cancer

Approximately 226,650 new lung and bronchus cancer cases were estimated in 2025. Lung cancer is strategically important because treatment increasingly combines systemic therapy with surgery, stereotactic radiation, conventional radiation, thermal ablation, and emerging tumor treating fields.

SBRT has created an important device market for early-stage patients who cannot undergo surgery, while ablation provides another option for selected lesions. The expansion of tumor treating fields into metastatic non-small-cell lung cancer further broadens the physical-device treatment ecosystem.

Colorectal, Liver and Pancreatic Cancer

Approximately 154,270 colorectal cancer cases were expected in 2025. Colorectal primary disease and liver metastases generate significant demand for surgical resection, robotic systems, radiation in selected cases, ablation, and catheter-directed liver therapy.

Primary and metastatic liver tumors are particularly important to the interventional oncology device market because they support embolization, microwave ablation, radiofrequency ablation, irreversible electroporation, and histotripsy. Pancreatic cancer is also becoming more important for device manufacturers following the emergence of advanced stereotactic treatment and the 2026 U.S. approval of tumor treating fields for locally advanced disease.

Brain and Central Nervous System Cancer

Brain and CNS tumors create a smaller patient population but a disproportionately technology-intensive treatment market. Stereotactic radiosurgery, precision radiation, advanced patient positioning, MRI-based planning, tumor treating fields, surgical navigation, and image-guided surgery are central technologies.

Complexity and the need to protect critical neurological structures support premium pricing and high clinical-value requirements.

Other Cancers

The remaining market includes gynecologic, head-and-neck, bladder, kidney, melanoma, sarcoma, bone, esophageal, gastric, thyroid, and other malignancies. Cervical and uterine cancers sustain brachytherapy demand; kidney cancer supports robotic surgery and ablation; head-and-neck disease requires highly conformal radiation planning; and bone metastases create demand for radiation, ablation, and palliative interventions.

 

By End User

Hospitals and Integrated Health Systems

Hospitals and integrated delivery networks represent the dominant purchasers by market value. They control most high-cost radiation equipment, robotic systems, complex surgical oncology procedures, inpatient cancer treatment, advanced interventional oncology, and multidisciplinary specialty programs.

Large health systems increasingly negotiate enterprise contracts covering equipment, consumables, software, maintenance, cybersecurity, training, and fleet management. For vendors, winning a system-level agreement can create much greater long-term value than winning an individual capital purchase.

Comprehensive and Specialty Cancer Centers

Comprehensive cancer centers are strategically critical because they treat complex cases, conduct clinical trials, influence guidelines, train specialists, and frequently serve as first adopters of emerging technologies. U.S. NCI-designated centers collectively create an influential installed-base opportunity for adaptive radiotherapy, radiosurgery, proton therapy, histotripsy, advanced ablation, robotics, and novel treatment platforms.

Freestanding Radiation Oncology Centers

Freestanding radiation centers remain an important buyer class for linear accelerators, stereotactic systems, planning technology, patient-positioning systems, quality assurance equipment, and service agreements.

These facilities place particularly strong emphasis on throughput, reimbursement stability, service responsiveness, total cost of ownership, financing flexibility, and utilization.

Ambulatory Surgery and Interventional Oncology Centers

Outpatient centers are becoming increasingly important for selected tumor ablation, surgery, and interventional oncology procedures. Migration is strongest where patients can be treated safely without major inpatient resources.

Technology designed for smaller footprints, predictable procedure times, lower staffing intensity, rapid room turnover, and recurring disposable revenue is likely to benefit from this shift.

Academic and Research Medical Centers

Academic medical centers often absorb the initial complexity of novel oncology technologies. They support clinical trials, investigator-led research, physician training, protocol development, and long-term evidence generation.

Commercial adoption frequently begins at these institutions before expanding into major regional systems and community cancer networks.

 

Regional Insights: Where the Market is Growing Fastest

The market is segmented into the South, West, Northeast, and Midwest, with regional differences driven by cancer case volume, population growth, age structure, treatment infrastructure, NCI-designated center concentration, payer mix, hospital capital capacity, and availability of radiation, surgical, and interventional oncology specialists.

The South is the largest regional market, while the West is expected to generate the fastest growth through 2035. The Northeast represents an especially high-value market for complex and research-intensive technologies, while the Midwest maintains a durable procedure base supported by major regional health systems and academic oncology networks.

South

The South represents the largest U.S. Cancer Treatment Devices Market and is estimated at approximately USD 4.36 billion in 2025, equivalent to about one-third of national market value. The region is projected to reach approximately USD 12.21 billion by 2035, representing an estimated CAGR of approximately 10.85%.

Using state cancer estimates grouped geographically, Southern states represented approximately 802,000 expected new cancer cases in 2025, or close to 39% of the national total. The region includes Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia, and the District of Columbia under the geographic framework used for this analysis.

Florida and Texas are the region’s two most commercially important state markets. Florida was expected to record approximately 171,960 new cancer cases in 2025, while Texas was expected to record approximately 150,870. Florida’s older population supports strong radiation oncology, prostate cancer, breast cancer, lung cancer, and interventional oncology demand. Texas combines high patient volume with large cancer networks, major academic centers, sophisticated surgical programs, and significant hospital capital capacity.

North Carolina, with approximately 71,320 estimated new cases, and Georgia, with approximately 66,210, are important growth markets because of expanding metro populations and strong academic oncology infrastructure. Virginia, Tennessee, South Carolina, Maryland, Kentucky, Alabama, Louisiana, Mississippi, Arkansas, Oklahoma, and West Virginia add substantial demand, although access to advanced treatment technology varies widely between urban referral centers and rural communities.

The South presents a particularly strong opportunity for technologies that increase treatment capacity. Population growth in Texas, Florida, North Carolina, Georgia, and Tennessee is creating pressure on oncology infrastructure, while rural areas require models that reduce patient travel. Short-course radiation, compact treatment platforms, regional hub-and-spoke oncology programs, and minimally invasive therapies therefore have strategic importance.

West

The West is estimated at approximately USD 3.30 billion in 2025 and is forecast to reach approximately USD 10.42 billion by 2035, representing the fastest regional CAGR at about 12.19%.

Approximately 424,000 new cancer cases were expected across Western states in 2025. The region includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

California dominates the regional market and was expected to record approximately 199,980 new cancer cases in 2025, the highest state-level total in the United States. Beyond patient volume, California has a dense concentration of academic medicine, cancer research, medtech investment, robotic surgery capability, digital-health development, and technology-oriented provider organizations. Consequently, the state is especially important for adaptive radiation therapy, advanced stereotactic systems, proton therapy, AI-enabled treatment planning, robotic oncology, and innovative ablation technologies.

Washington, Arizona, Colorado, and Oregon are also meaningful markets. Washington was expected to record approximately 46,500 new cases, Arizona 42,560, Colorado 29,020, and Oregon 26,980 in 2025. Arizona and Nevada benefit from population growth and aging demographics, while Washington, Colorado, and Utah have strong integrated delivery systems and high adoption of digitally connected clinical workflows.

The West’s growth advantage is likely to come from technology intensity rather than cancer burden alone. Large providers increasingly evaluate enterprise radiation platforms, software-driven workflows, advanced robotics, digital planning, and treatment automation. The region is therefore particularly attractive for manufacturers launching high-value technologies requiring sophisticated clinical adoption and strong physician champions.

Northeast

The Northeast accounted for an estimated USD 3.04 billion in 2025 and is projected to approach approximately USD 7.92 billion by 2035, reflecting a CAGR of about 10.05%.

Approximately 375,000 new cancer cases were expected across the Northeast in 2025. The region includes Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont.

New York is the region’s largest state opportunity, with approximately 123,430 estimated new cancer cases in 2025. Pennsylvania followed with approximately 90,240, New Jersey with 59,840, Massachusetts with 44,000, and Connecticut with 23,920.

The Northeast is particularly influential because of the density of academic medical centers, comprehensive cancer programs, clinical trial activity, specialist expertise, and complex referral patterns. Treatment-device adoption is often evidence-intensive. Novel radiation platforms, advanced radiosurgery, image-guided robotic procedures, specialized brachytherapy, interventional oncology, and new physical treatment technologies are frequently evaluated in major Northeastern centers before broader commercialization.

Procurement can nevertheless be challenging. Hospitals face high labor costs, strong capital governance, constrained physical space, and sophisticated value-analysis requirements. Vendors therefore need a rigorous economic case built around utilization, workflow, capacity, treatment time, service cost, and measurable clinical differentiation.

The Northeast is unlikely to match the West’s percentage growth because several markets are mature, but its premium technology mix means it should remain one of the most commercially valuable regions per cancer-treatment episode.

Midwest

The Midwest is estimated at approximately USD 2.50 billion in 2025 and is projected to reach approximately USD 6.26 billion by 2035, equivalent to an estimated CAGR of around 9.61%.

Approximately 441,000 new cancer cases were expected across Midwestern states in 2025, demonstrating that the region’s cancer burden is larger than its device-market value share would imply. The region includes Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin.

Illinois and Ohio are the largest state markets, with approximately 78,870 and 77,010 expected new cancer cases, respectively, in 2025. Michigan accounted for approximately 66,040, Indiana 42,150, Wisconsin 39,940, Missouri 39,220, and Minnesota 37,650.

Chicago, Cleveland, Columbus, Detroit, Minneapolis, St. Louis, Indianapolis, and other major metropolitan centers contain sophisticated oncology programs capable of adopting advanced radiation, robotic, ablation, and interventional technologies. Minnesota also has strategic importance because of its medtech ecosystem and expertise in device innovation.

More rural Midwestern states create a different opportunity. Long travel distances and lower specialist density can make conventional multi-week treatment burdensome. Technologies supporting hypofractionation, treatment automation, tele-planning, remote service, smaller capital footprints, and regional cancer networks can therefore create material clinical and economic value.

Growth is expected to remain somewhat slower than in the West and South, but the Midwest will continue to provide durable replacement demand and attractive opportunities for manufacturers offering reliable systems, predictable service, strong clinical education, and compelling total-cost-of-ownership economics.

 

Key Market Players

The U.S. Cancer Treatment Devices Competitive Landscape is fragmented across radiation oncology, robotic surgery, interventional oncology, tumor ablation, proton therapy, brachytherapy, tumor treating fields, treatment planning, and image-guided intervention. No single manufacturer controls the complete treatment pathway.

Some of the key companies relevant to the U.S. market are Siemens Healthineers/Varian, Elekta, Accuray Incorporated, Ion Beam Applications (IBA), Mevion Medical Systems, RefleXion Medical, ZAP Surgical, Novocure, HistoSonics, Intuitive Surgical, Johnson & Johnson MedTech, Medtronic, Boston Scientific, AngioDynamics, Stryker, Terumo, Merit Medical Systems, Profound Medical, EDAP TMS, GT Medical Technologies, Theragenics, Perspective Therapeutics/Isoray-related brachytherapy assets, Brainlab, RaySearch Laboratories, and C-RAD.

Siemens Healthineers through Varian remains one of the most important competitors because of its broad radiation oncology portfolio, installed base, software capabilities, treatment planning, and service organization. Elekta competes strongly in linear accelerators, radiosurgery, brachytherapy, treatment software, and digitally integrated oncology. Accuray participates through CyberKnife and Radixact technologies, while IBA and Mevion compete in particle therapy.

RefleXion is strategically differentiated through biology-guided radiation therapy. ZAP Surgical focuses on radiosurgery, and Brainlab, RaySearch, and C-RAD influence planning, positioning, workflow, and treatment accuracy.

Outside conventional radiation, Novocure has established an emerging field-based treatment platform through tumor treating fields, while HistoSonics is building a new category around histotripsy. Intuitive Surgical is highly relevant to oncology through robotic prostate, kidney, colorectal, thoracic, and gynecologic surgery.

Boston Scientific, Medtronic, AngioDynamics, Merit Medical, Terumo, and other interventional companies compete across ablation, embolization, catheter delivery, and image-guided oncology procedures.

Competitive advantage through 2035 will increasingly depend on platform breadth, clinical evidence, installed-base access, service reliability, physician training, AI integration, software architecture, reimbursement support, capital-financing flexibility, consumable economics, and enterprise contracting.

 

Recent Developments

Recent developments demonstrate that the U.S. Cancer Treatment Devices Market is expanding beyond conventional radiotherapy and surgery.

In October 2024, the FDA approved Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic non-small-cell lung cancer who had progressed on or after platinum-based treatment. The approval expanded tumor treating fields into one of the largest U.S. cancer indications and strengthened the commercial case for longitudinal, home-based physical oncology treatment.

The FDA’s 2024 oncology device review also highlighted multiple AI/ML-based technologies associated with radiation treatment planning, secondary checks, and automated contouring. This signals a broader regulatory transition in which software is becoming an integral component of treatment-device differentiation.

The HistoSonics Edison System received De Novo authorization for focused-ultrasound-based non-thermal mechanical tissue ablation of liver tumors. Histotripsy is commercially significant because it introduces a fundamentally different mechanism from surgery, cryotherapy, radiofrequency ablation, or microwave ablation and creates a potential new category within interventional oncology.

The RefleXion Medical Radiotherapy System established another new technological direction by combining a linear accelerator with PET capabilities for biology-guided radiation treatment of targets including lung and bone lesions. While clinical adoption remains developing, biology-guided therapy illustrates how molecular or functional information may increasingly influence real-time physical treatment delivery.

In January 2026, FDA records documented clearance activity involving the Elekta Evo and other Elekta medical linear accelerator configurations, reinforcing the continuing replacement and upgrade cycle across radiation oncology.

In February 2026, the FDA approved Optune Pax for adult patients with locally advanced pancreatic cancer. The device delivers tumor treating fields through a portable, non-invasive platform and represents an important expansion of physical oncology treatment into pancreatic cancer, where treatment options have historically been limited.

Reimbursement is evolving at the same time. Medicare’s 2026 physician payment framework uses hospital outpatient data to inform rate setting for certain radiation treatment services. For manufacturers, this strengthens the importance of understanding technical-component economics, site of service, episode efficiency, treatment utilization, and the downstream financial implications of shorter or more automated treatment workflows.

Over the next several years, the market is likely to see continued consolidation. Large medtech companies have strategic incentives to acquire differentiated oncology platforms that add recurring consumables, proprietary software, installed-base leverage, or access to rapidly expanding procedural specialties.

 

Conclusion

The U.S. Cancer Treatment Devices Market Size & Share is positioned for strong expansion from approximately USD 13.20 billion in 2025 to USD 36.81 billion by 2035, representing an estimated 10.80% CAGR during 2026–2035.

Its long-term opportunity is supported by an annual cancer burden exceeding 2 million newly diagnosed patients, extensive cancer-care infrastructure, strong treatment-device utilization, significant hospital capital spending, and continuous innovation in radiation oncology, interventional oncology, robotics, tumor ablation, histotripsy, tumor treating fields, and software-enabled treatment.

Radiation oncology will remain the largest device category, but the fastest incremental value creation is expected to occur where technology expands treatment eligibility or changes workflow economics. Adaptive radiotherapy, stereotactic treatment, proton therapy, tumor ablation, histotripsy, biology-guided radiation, tumor treating fields, and robotic oncology are therefore among the most strategically attractive areas.

Hospitals will increasingly judge capital technologies on measurable economic performance. Treatment capacity per room, procedure duration, staffing requirements, software automation, service uptime, consumable costs, reimbursement, patient travel, complication rates, length of stay, and ability to support outpatient treatment will influence purchase decisions alongside clinical effectiveness.

Regionally, the South is expected to remain the largest U.S. market, supported by patient volume, population growth, and expanding oncology networks. The West is projected to record the fastest growth because of high technology adoption and strong clinical innovation. The Northeast will retain a premium, evidence-driven treatment mix, while the Midwest will provide a stable base for replacement equipment and advanced regional cancer programs.

At the state level, California, Florida, Texas, New York, Pennsylvania, Illinois, Ohio, North Carolina, Michigan, Georgia, New Jersey, Virginia, Washington, Massachusetts, and Arizona will be particularly significant to equipment manufacturers, distributors, investors, and oncology service providers because of their combination of cancer case volume and treatment infrastructure.

For clients assessing the U.S. Cancer Treatment Devices Market, the central strategic issue is not simply whether device expenditure will increase. The more valuable questions are which treatment modalities will expand the addressable patient pool, which technologies can justify capital replacement ahead of schedule, how reimbursement will affect site-of-care economics, where procedure volume will migrate, and which vendors can convert clinical differentiation into sustainable installed-base and recurring-revenue advantage.

The companies best positioned through 2035 will be those capable of combining precise treatment delivery with automation, evidence generation, workflow efficiency, favorable care economics, scalable physician training, strong service infrastructure, and an integrated technology platform rather than competing exclusively on hardware performance.

 

TABLE OF CONTENT

1. U.S. Cancer Treatment Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Market Forecasting Models
1.3.6. Data Triangulation, Validation and Final Report Publishing
1.4. Key Market Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Cancer Treatment Device Manufacturers
1.6.2. Radiation Oncology Equipment and Component Suppliers
1.6.3. Hospitals and Integrated Delivery Networks
1.6.4. Comprehensive and Specialty Cancer Centers
1.6.5. Radiation Oncology, Surgical Oncology and Interventional Oncology Providers
1.6.6. Ambulatory Surgery Centers and Outpatient Treatment Facilities
1.6.7. Group Purchasing Organizations, Distributors and Specialty Suppliers
1.6.8. Payers, FDA, CMS and Oncology Clinical Decision-Makers

What this section provides: This section defines the U.S. Cancer Treatment Devices Market boundary, inclusion and exclusion criteria, study methodology, assumptions, validation framework, and stakeholder ecosystem so clients clearly understand how the market is measured and forecast.

2. U.S. Cancer Treatment Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size, CAGR and Growth Trajectory
2.8. High-Growth Treatment Technology Opportunity Areas
2.9. Key Oncology Capital Investment Themes
2.10. Major Strategic Takeaways for Market Participants

What this section provides: This section gives decision-makers a concise assessment of market size, historical development, 2025 positioning, 2026–2035 growth outlook, technology priorities, competitive intensity, and the most commercially attractive cancer treatment device opportunities.

3. U.S. Cancer Treatment Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Expanding Treatment Population
3.1.2. Growing Utilization of Precision Radiation Therapy
3.1.3. Expansion of Minimally Invasive Interventional Oncology Procedures
3.1.4. Growth in Robotic and Image-Guided Cancer Surgery
3.1.5. Radiation Oncology Installed-Base Replacement and Modernization
3.1.6. Increasing Adoption of Stereotactic and Hypofractionated Treatment
3.1.7. Growing Demand for Patient-Specific and Organ-Sparing Therapy

3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Cancer Treatment Systems
3.2.2. Reimbursement Pressure and Treatment Episode Economics
3.2.3. Long Capital Replacement Cycles for Radiation Oncology Systems
3.2.4. Radiation Oncologist, Medical Physicist and Specialist Workforce Constraints
3.2.5. High Installation, Infrastructure and Service Requirements
3.2.6. Clinical Evidence Requirements for Emerging Treatment Modalities

3.3. Opportunities and Their Impact Analysis
3.3.1. Adaptive Radiation Therapy and AI-Assisted Treatment Planning
3.3.2. Histotripsy and Non-Thermal Tumor Destruction
3.3.3. Tumor Treating Fields Expansion into New Cancer Indications
3.3.4. Compact Proton Therapy and Next-Generation Particle Therapy Systems
3.3.5. Expansion of Image-Guided Tumor Ablation
3.3.6. Growth of Outpatient and Ambulatory Cancer Treatment
3.3.7. Biology-Guided and Molecularly Informed Radiation Treatment

3.4. Challenges and Their Impact Analysis
3.4.1. Technology Obsolescence and Software Upgrade Requirements
3.4.2. Complex Hospital Capital Approval Processes
3.4.3. Treatment Standardization Across Multisite Oncology Networks
3.4.4. Cybersecurity and Interoperability Requirements
3.4.5. Evidence-to-Reimbursement Commercialization Gap

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Radiation Oncology Treatment-Room Utilization Analysis
3.8. Hospital Capital Procurement Behavior Analysis
3.9. Oncology Procedure Migration and Site-of-Care Analysis

What this section provides: This section explains the clinical, commercial, reimbursement, technological and operational forces shaping demand for cancer treatment devices and helps clients identify both high-growth opportunities and market-entry risks.

4. U.S. Cancer Treatment Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Cancer Treatment Device Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Oncology Capital Equipment Installed-Base and Replacement-Cycle Analysis
4.6. Impact of Digitalization, AI and Connected Oncology Workflows
4.7. Application & Innovation Landscape
4.8. FDA Regulatory Framework Analysis
4.9. CMS Reimbursement and Coverage Landscape
4.10. Medicare Radiation Oncology Payment Environment
4.11. Import/Export Restrictions & Tariff Impact
4.12. U.S. Government Cancer Initiatives and Public Health Programs
4.13. NCI and Comprehensive Cancer Center Infrastructure Analysis
4.14. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.15. Hospital Value Analysis Committee Decision Framework
4.16. Total Cost of Ownership Analysis for Oncology Capital Equipment

What this section provides: This section provides a comprehensive view of the external market environment, including regulation, reimbursement, pricing, capital equipment economics, supply chains, technology adoption, government initiatives, installed-base dynamics, and hospital procurement considerations.

5. U.S. Cancer Treatment Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)

5.1.2. External Beam Radiation Therapy, Radiosurgery & Particle Therapy Systems
5.1.2.1. Medical Linear Accelerators
5.1.2.2. Image-Guided Radiation Therapy Systems
5.1.2.3. Stereotactic Radiosurgery Systems
5.1.2.4. Stereotactic Body Radiation Therapy Systems
5.1.2.5. Proton Therapy Systems
5.1.2.6. Other Particle Therapy Systems
5.1.2.7. Treatment Planning, Positioning and Motion Management Systems

5.1.3. Brachytherapy Systems & Applicators
5.1.3.1. High-Dose-Rate Brachytherapy Systems
5.1.3.2. Low-Dose-Rate Brachytherapy Systems
5.1.3.3. Electronic Brachytherapy Systems
5.1.3.4. Brachytherapy Applicators, Catheters and Needles
5.1.3.5. Seed Placement and Treatment Delivery Accessories

5.1.4. Tumor Ablation & Histotripsy Devices
5.1.4.1. Microwave Ablation Devices
5.1.4.2. Radiofrequency Ablation Devices
5.1.4.3. Cryoablation Devices
5.1.4.4. Irreversible Electroporation Systems
5.1.4.5. High-Intensity Focused Ultrasound Systems
5.1.4.6. Histotripsy Systems
5.1.4.7. Ablation Probes and Procedure-Specific Consumables

5.1.5. Interventional Oncology & Embolization Devices
5.1.5.1. Embolization Systems
5.1.5.2. Microcatheters and Delivery Catheters
5.1.5.3. Guidewires and Access Devices
5.1.5.4. Embolic Particles and Microsphere Delivery Systems
5.1.5.5. Radioembolization Support and Delivery Devices
5.1.5.6. Image-Guided Interventional Oncology Accessories

5.1.6. Tumor Treating Fields & Oncology-Specific Robotic/Surgical Platforms
5.1.6.1. Tumor Treating Fields Devices
5.1.6.2. Robotic Surgical Platforms Used in Oncology
5.1.6.3. Oncology Surgical Energy Systems
5.1.6.4. Tumor Resection and Tissue Destruction Systems
5.1.6.5. Procedure-Specific Instruments and Consumables

What this section provides: This section identifies the cancer treatment device categories expected to contribute the largest revenue pools and highlights emerging product technologies likely to generate disproportionate growth through 2035.

6. U.S. Cancer Treatment Devices Market – By Treatment Modality

6.1. Overview
6.1.1. Segment Share Analysis, By Treatment Modality, 2025 & 2035 (%)

6.1.2. Radiation-Based Local Treatment
6.1.2.1. Conventional External Beam Radiation Therapy
6.1.2.2. Intensity-Modulated Radiation Therapy
6.1.2.3. Image-Guided Radiation Therapy
6.1.2.4. Stereotactic Radiosurgery
6.1.2.5. Stereotactic Body Radiation Therapy
6.1.2.6. Proton and Particle Therapy
6.1.2.7. Brachytherapy

6.1.3. Thermal Tumor Ablation
6.1.3.1. Microwave Ablation
6.1.3.2. Radiofrequency Ablation
6.1.3.3. Laser-Based Ablation
6.1.3.4. Other Thermal Ablation Procedures

6.1.4. Cryoablation & Non-Thermal Tissue Destruction
6.1.4.1. Cryoablation
6.1.4.2. Irreversible Electroporation
6.1.4.3. Histotripsy
6.1.4.4. Focused Ultrasound-Based Treatment

6.1.5. Catheter-Based Locoregional Treatment
6.1.5.1. Transarterial Embolization
6.1.5.2. Chemoembolization-Associated Device Procedures
6.1.5.3. Radioembolization-Associated Device Procedures
6.1.5.4. Other Image-Guided Locoregional Interventions

6.1.6. Surgical, Robotic & Field-Based Treatment
6.1.6.1. Conventional Surgical Oncology Device Procedures
6.1.6.2. Robot-Assisted Cancer Surgery
6.1.6.3. Minimally Invasive Surgical Oncology
6.1.6.4. Tumor Treating Fields Therapy
6.1.6.5. Other Physical Oncology Treatment Modalities

What this section provides: This section evaluates how different physical cancer treatment modalities contribute to market value and identifies technologies positioned to benefit from precision treatment, minimally invasive care, shortened treatment courses, and outpatient migration.

7. U.S. Cancer Treatment Devices Market – By Cancer Type

7.1. Overview
7.1.1. Segment Share Analysis, By Cancer Type, 2025 & 2035 (%)

7.1.2. Breast Cancer
7.1.2.1. Radiation Therapy Devices
7.1.2.2. Surgical Oncology Devices
7.1.2.3. Brachytherapy and Local Treatment Devices

7.1.3. Prostate Cancer
7.1.3.1. Robotic Surgical Devices
7.1.3.2. External Beam and Stereotactic Radiation Devices
7.1.3.3. Brachytherapy Devices
7.1.3.4. Cryoablation and Focal Therapy Devices

7.1.4. Lung Cancer
7.1.4.1. Stereotactic Radiation Systems
7.1.4.2. Surgical and Robotic Devices
7.1.4.3. Tumor Ablation Devices
7.1.4.4. Tumor Treating Fields Devices

7.1.5. Colorectal Cancer
7.1.5.1. Surgical and Robotic Treatment Devices
7.1.5.2. Radiation Treatment Systems
7.1.5.3. Local and Metastatic Tumor Treatment Devices

7.1.6. Liver Cancer and Hepatic Metastases
7.1.6.1. Tumor Ablation Devices
7.1.6.2. Histotripsy Systems
7.1.6.3. Embolization Devices
7.1.6.4. Radiation and Radiosurgery Systems

7.1.7. Pancreatic Cancer
7.1.7.1. Radiation Treatment Systems
7.1.7.2. Irreversible Electroporation Systems
7.1.7.3. Tumor Treating Fields Devices
7.1.7.4. Surgical Treatment Devices

7.1.8. Brain & Central Nervous System Cancer
7.1.8.1. Stereotactic Radiosurgery Systems
7.1.8.2. Precision Radiation Therapy Systems
7.1.8.3. Tumor Treating Fields Devices
7.1.8.4. Surgical Navigation and Treatment Platforms

7.1.9. Other Cancers
7.1.9.1. Gynecologic Cancers
7.1.9.2. Kidney Cancer
7.1.9.3. Head & Neck Cancer
7.1.9.4. Bladder Cancer
7.1.9.5. Bone and Soft Tissue Cancers
7.1.9.6. Other Solid Tumors

What this section provides: This section helps clients understand treatment-device demand by cancer indication and identify tumor types with the strongest procedure volumes, technology intensity, treatment innovation, and addressable device opportunity.

8. U.S. Cancer Treatment Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)

8.1.2. Hospitals and Integrated Health Systems
8.1.2.1. Large Academic Hospitals
8.1.2.2. Integrated Delivery Networks
8.1.2.3. Community Hospitals with Oncology Programs

8.1.3. Comprehensive and Specialty Cancer Centers
8.1.3.1. NCI-Designated Cancer Centers
8.1.3.2. Independent Comprehensive Cancer Centers
8.1.3.3. Multisite Oncology Networks

8.1.4. Freestanding Radiation Oncology Centers
8.1.4.1. Independent Radiation Oncology Practices
8.1.4.2. Health-System-Affiliated Radiation Centers
8.1.4.3. Multisite Radiation Oncology Networks

8.1.5. Ambulatory Surgery & Interventional Oncology Centers
8.1.5.1. Ambulatory Surgery Centers
8.1.5.2. Outpatient Tumor Ablation Centers
8.1.5.3. Interventional Radiology and Oncology Facilities

8.1.6. Academic & Research Medical Centers
8.1.6.1. University Medical Centers
8.1.6.2. Clinical Trial Centers
8.1.6.3. Translational Oncology Research Facilities

What this section provides: This section explains which U.S. care settings are expected to drive capital purchases, procedural consumable demand, emerging technology adoption, replacement cycles, and cancer treatment device utilization through 2035.

9. U.S. Cancer Treatment Devices Market – By Geography
9.1. Introduction

9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Cancer Incidence and Treatment Population Analysis
9.1.4. Regional Oncology Procedure Volume Analysis
9.1.5. Regional Radiation Oncology and Cancer Center Infrastructure Analysis
9.1.6. Regional Capital Procurement and Replacement-Cycle Dynamics
9.1.7. Regional Reimbursement and Site-of-Care Analysis

9.2. West Region

9.2.1. Regional Overview & Trends
9.2.2. West Region Cancer Treatment Device Manufacturers and Procurement Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.8. California

9.2.8.1. Overview
9.2.8.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.8.3. California Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.8.4. California Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.8.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.9. Washington

9.2.9.1. Overview
9.2.9.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.9.3. Washington Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.9.4. Washington Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.9.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.10. Arizona

9.2.10.1. Overview
9.2.10.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.10.3. Arizona Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.10.4. Arizona Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.10.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.11. Colorado

9.2.11.1. Overview
9.2.11.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.11.3. Colorado Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.11.4. Colorado Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.11.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.12. Oregon

9.2.12.1. Overview
9.2.12.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.12.3. Oregon Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.12.4. Oregon Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.12.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.13. Utah

9.2.13.1. Overview
9.2.13.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.13.3. Utah Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.13.4. Utah Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.13.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.14. Nevada

9.2.14.1. Overview
9.2.14.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.14.3. Nevada Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.14.4. Nevada Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.14.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.15. New Mexico

9.2.15.1. Overview
9.2.15.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.15.3. New Mexico Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.15.4. New Mexico Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.15.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.16. Idaho

9.2.16.1. Overview
9.2.16.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.16.3. Idaho Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.16.4. Idaho Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.16.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.17. Montana

9.2.17.1. Overview
9.2.17.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.17.3. Montana Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.17.4. Montana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.17.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.18. Wyoming

9.2.18.1. Overview
9.2.18.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.18.3. Wyoming Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.18.4. Wyoming Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.18.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.19. Alaska

9.2.19.1. Overview
9.2.19.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.19.3. Alaska Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.19.4. Alaska Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.19.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.20. Hawaii

9.2.20.1. Overview
9.2.20.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.20.3. Hawaii Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.2.20.4. Hawaii Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.2.20.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3. Northeast Region

9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Cancer Treatment Device Manufacturers and Procurement Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.8. New York

9.3.8.1. Overview
9.3.8.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.8.3. New York Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.8.4. New York Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.8.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.9. Massachusetts

9.3.9.1. Overview
9.3.9.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.9.3. Massachusetts Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.9.4. Massachusetts Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.9.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.10. New Jersey

9.3.10.1. Overview
9.3.10.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.10.3. New Jersey Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.10.4. New Jersey Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.10.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.11. Pennsylvania

9.3.11.1. Overview
9.3.11.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.11.3. Pennsylvania Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.11.4. Pennsylvania Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.11.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.12. Connecticut

9.3.12.1. Overview
9.3.12.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.12.3. Connecticut Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.12.4. Connecticut Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.12.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.13. Maine

9.3.13.1. Overview
9.3.13.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.13.3. Maine Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.13.4. Maine Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.13.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.14. Vermont

9.3.14.1. Overview
9.3.14.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.14.3. Vermont Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.14.4. Vermont Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.14.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.15. New Hampshire

9.3.15.1. Overview
9.3.15.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.15.3. New Hampshire Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.15.4. New Hampshire Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.15.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.16. Rhode Island

9.3.16.1. Overview
9.3.16.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.16.3. Rhode Island Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.16.4. Rhode Island Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.16.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.17. Delaware

9.3.17.1. Overview
9.3.17.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.17.3. Delaware Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.3.17.4. Delaware Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.3.17.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4. South Region

9.4.1. Regional Overview & Trends
9.4.2. South Region Cancer Treatment Device Manufacturers and Procurement Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.8. Texas

9.4.8.1. Overview
9.4.8.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.8.3. Texas Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.8.4. Texas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.8.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.9. Florida

9.4.9.1. Overview
9.4.9.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.9.3. Florida Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.9.4. Florida Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.9.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.10. Georgia

9.4.10.1. Overview
9.4.10.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.10.3. Georgia Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.10.4. Georgia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.10.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.11. North Carolina

9.4.11.1. Overview
9.4.11.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.11.3. North Carolina Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.11.4. North Carolina Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.11.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.12. Tennessee

9.4.12.1. Overview
9.4.12.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.12.3. Tennessee Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.12.4. Tennessee Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.12.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.13. South Carolina

9.4.13.1. Overview
9.4.13.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.13.3. South Carolina Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.13.4. South Carolina Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.13.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.14. Alabama

9.4.14.1. Overview
9.4.14.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.14.3. Alabama Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.14.4. Alabama Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.14.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.15. Mississippi

9.4.15.1. Overview
9.4.15.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.15.3. Mississippi Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.15.4. Mississippi Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.15.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.16. Louisiana

9.4.16.1. Overview
9.4.16.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.16.3. Louisiana Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.16.4. Louisiana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.16.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.17. Arkansas

9.4.17.1. Overview
9.4.17.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.17.3. Arkansas Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.17.4. Arkansas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.17.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.18. Kentucky

9.4.18.1. Overview
9.4.18.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.18.3. Kentucky Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.18.4. Kentucky Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.18.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.19. Oklahoma

9.4.19.1. Overview
9.4.19.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.19.3. Oklahoma Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.19.4. Oklahoma Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.19.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.20. Virginia

9.4.20.1. Overview
9.4.20.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.20.3. Virginia Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.20.4. Virginia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.20.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.21. Maryland

9.4.21.1. Overview
9.4.21.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.21.3. Maryland Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.21.4. Maryland Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.21.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.22. West Virginia

9.4.22.1. Overview
9.4.22.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.22.3. West Virginia Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.4.22.4. West Virginia Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.4.22.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5. Midwest Region

9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Cancer Treatment Device Manufacturers and Procurement Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.8. Illinois

9.5.8.1. Overview
9.5.8.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.8.3. Illinois Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.8.4. Illinois Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.8.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.9. Ohio

9.5.9.1. Overview
9.5.9.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.9.3. Ohio Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.9.4. Ohio Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.9.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.10. Michigan

9.5.10.1. Overview
9.5.10.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.10.3. Michigan Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.10.4. Michigan Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.10.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.11. Minnesota

9.5.11.1. Overview
9.5.11.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.11.3. Minnesota Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.11.4. Minnesota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.11.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.12. Indiana

9.5.12.1. Overview
9.5.12.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.12.3. Indiana Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.12.4. Indiana Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.12.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.13. Wisconsin

9.5.13.1. Overview
9.5.13.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.13.3. Wisconsin Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.13.4. Wisconsin Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.13.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.14. Missouri

9.5.14.1. Overview
9.5.14.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.14.3. Missouri Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.14.4. Missouri Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.14.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.15. Iowa

9.5.15.1. Overview
9.5.15.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.15.3. Iowa Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.15.4. Iowa Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.15.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.16. Kansas

9.5.16.1. Overview
9.5.16.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.16.3. Kansas Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.16.4. Kansas Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.16.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.17. Nebraska

9.5.17.1. Overview
9.5.17.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.17.3. Nebraska Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.17.4. Nebraska Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.17.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.18. North Dakota

9.5.18.1. Overview
9.5.18.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.18.3. North Dakota Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.18.4. North Dakota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.18.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.19. South Dakota

9.5.19.1. Overview
9.5.19.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.19.3. South Dakota Market Size and Forecast, By Treatment Modality, 2021–2035 (US$ Billion)
9.5.19.4. South Dakota Market Size and Forecast, By Cancer Type, 2021–2035 (US$ Billion)
9.5.19.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis across all 50 states, helping clients identify cancer-treatment demand centers, oncology infrastructure clusters, radiation and interventional procedure hubs, capital-equipment replacement opportunities, emerging technology adoption hotspots, and state-level commercial opportunities.

10. U.S. Cancer Treatment Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Competitive Benchmarking by Product Category
10.3. Competitive Benchmarking by Treatment Modality
10.4. Company Positioning Matrix
10.4.1. Leaders
10.4.2. Challengers
10.4.3. Innovators
10.4.4. Emerging Players

10.5. Company Profiles

10.5.1. Siemens Healthineers / Varian
10.5.2. Elekta AB
10.5.3. Accuray Incorporated
10.5.4. Ion Beam Applications SA
10.5.5. Mevion Medical Systems
10.5.6. RefleXion Medical
10.5.7. ZAP Surgical Systems
10.5.8. Novocure
10.5.9. HistoSonics
10.5.10. Intuitive Surgical
10.5.11. Johnson & Johnson MedTech
10.5.12. Medtronic
10.5.13. Boston Scientific Corporation
10.5.14. AngioDynamics
10.5.15. Stryker Corporation
10.5.16. Terumo Interventional Systems
10.5.17. Merit Medical Systems
10.5.18. Profound Medical
10.5.19. EDAP TMS
10.5.20. GT Medical Technologies
10.5.21. Theragenics Corporation
10.5.22. Brainlab
10.5.23. RaySearch Laboratories
10.5.24. C-RAD
10.5.25. Eckert & Ziegler BEBIG

10.6. Company Profile Assessment Framework
10.6.1. Company Overview
10.6.2. Cancer Treatment Device Portfolio
10.6.3. U.S. Market Strategy
10.6.4. Financial and Commercial Positioning
10.6.5. Clinical Evidence and Product Pipeline
10.6.6. FDA Regulatory Updates
10.6.7. Partnerships, Acquisitions and Strategic Collaborations
10.6.8. Recent Developments
10.6.9. Competitive Strengths and Strategic Risks

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, installed-base intelligence, innovation direction, regulatory activity, pipeline assessment, and strategic intelligence on 25 important companies participating in the U.S. cancer treatment device ecosystem.

11. U.S. Cancer Treatment Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario

11.2. Disruptive Technologies Impact
11.2.1. AI-Assisted Adaptive Radiation Therapy
11.2.2. Biology-Guided Radiation Therapy
11.2.3. Histotripsy and Non-Thermal Mechanical Tumor Destruction
11.2.4. Tumor Treating Fields
11.2.5. Compact Proton and Advanced Particle Therapy
11.2.6. Robotic and Image-Guided Oncology Intervention
11.2.7. Automated Treatment Planning and Digital Oncology Workflow Platforms

11.3. Oncology Capital Equipment Replacement Outlook
11.4. Future Site-of-Care Migration Analysis
11.5. Emerging Business Models
11.6. Recurring Consumables and Software Revenue Opportunities
11.7. Business Opportunities for Startups and Existing Players
11.8. Investment Prioritization Matrix
11.9. Technology Commercialization Risk Matrix
11.10. High-Growth Opportunity Map, 2026–2035

What this section provides: This section prepares clients for future technology disruption, oncology capital replacement cycles, changing treatment workflows, emerging business models, investment opportunities, and alternative market adoption scenarios through 2035.

12. U.S. Cancer Treatment Devices Market: Strategic Recommendations

12.1. Recommendations for Cancer Treatment Device Manufacturers
12.2. Recommendations for Radiation Oncology Equipment Companies
12.3. Recommendations for Hospitals and Integrated Health Systems
12.4. Recommendations for Comprehensive Cancer Centers
12.5. Recommendations for Investors and Private Equity Firms
12.6. Recommendations for Distributors and Channel Partners
12.7. Recommendations for New Entrants and Startups
12.8. Go-to-Market Strategy Considerations
12.9. FDA and Reimbursement Commercialization Strategy
12.10. Product Positioning and Portfolio Expansion Guidance
12.11. Hospital Capital Procurement Engagement Strategy
12.12. Physician Training and Clinical Adoption Strategy
12.13. Regional and State-Level Commercial Prioritization
12.14. Partnership, Licensing and M&A Opportunity Framework

What this section provides: This section converts U.S. Cancer Treatment Devices Market intelligence into actionable recommendations for product strategy, commercialization, investment, market entry, physician adoption, hospital contracting, regional expansion, partnerships, and competitive differentiation.

13. U.S. Cancer Treatment Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Market Definition and Inclusion Limitation
13.3. Data Use Limitation
13.4. Forecasting Limitation
13.5. Regulatory and Reimbursement Information Limitation
13.6. Legal Disclaimer
13.7. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s market-scope limitations, data-use boundaries, forecasting assumptions, regulatory and reimbursement limitations, third-party data considerations, and applicable legal disclaimers.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Cancer Treatment Devices Market: Market Definition and Scope
TABLE 3: U.S. Cancer Treatment Devices Market: Research Methodology Framework
TABLE 4: U.S. Cancer Treatment Devices Market: Key Market Assumptions
TABLE 5: U.S. Cancer Treatment Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Cancer Treatment Devices Market: Stakeholder Analysis
TABLE 7: U.S. Cancer Treatment Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Cancer Treatment Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Cancer Treatment Devices Market: Market Attractiveness Index
TABLE 10: U.S. Cancer Treatment Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Cancer Treatment Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Cancer Treatment Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Cancer Treatment Devices Market: High-Growth Opportunity Areas
TABLE 14: U.S. Cancer Treatment Devices Market: Drivers & Impact Analysis
TABLE 15: U.S. Cancer Treatment Devices Market: Restraints & Impact Analysis
TABLE 16: U.S. Cancer Treatment Devices Market: Opportunities & Impact Analysis
TABLE 17: U.S. Cancer Treatment Devices Market: Challenges & Impact Analysis
TABLE 18: U.S. Cancer Treatment Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Cancer Treatment Devices Market: Clinical Workflow Economics Matrix
TABLE 20: U.S. Cancer Treatment Devices Market: Radiation Oncology Treatment-Room Utilization Matrix
TABLE 21: U.S. Cancer Treatment Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 22: U.S. Cancer Treatment Devices Market: Site-of-Care Migration Analysis
TABLE 23: U.S. Cancer Treatment Devices Market: PESTEL Analysis
TABLE 24: U.S. Cancer Treatment Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Cancer Treatment Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 26: U.S. Cancer Treatment Devices Market: Value Chain Analysis
TABLE 27: U.S. Cancer Treatment Devices Market: Supply Chain Analysis
TABLE 28: U.S. Cancer Treatment Devices Market: Oncology Capital Equipment Installed-Base & Replacement-Cycle Analysis
TABLE 29: U.S. Cancer Treatment Devices Market: Digitalization and AI Impact
TABLE 30: U.S. Cancer Treatment Devices Market: Application & Innovation Landscape
TABLE 31: U.S. Cancer Treatment Devices Market: FDA Regulatory Framework Analysis
TABLE 32: U.S. Cancer Treatment Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 33: U.S. Cancer Treatment Devices Market: Medicare Radiation Oncology Payment Environment
TABLE 34: U.S. Cancer Treatment Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 35: U.S. Cancer Treatment Devices Market: U.S. Government Cancer Initiatives
TABLE 36: U.S. Cancer Treatment Devices Market: NCI and Cancer Center Infrastructure Analysis
TABLE 37: U.S. Cancer Treatment Devices Market: Geopolitical and Supply-Chain Risk Analysis
TABLE 38: U.S. Cancer Treatment Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 39: U.S. Cancer Treatment Devices Market: Total Cost of Ownership Analysis
TABLE 40: U.S. Cancer Treatment Devices Market: Product Category Snapshot, 2025
TABLE 41: Segment Dashboard; Definition and Scope, by Product Category
TABLE 42: U.S. Cancer Treatment Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 43: U.S. Cancer Treatment Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 44: External Beam Radiation Therapy, Radiosurgery & Particle Therapy Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Brachytherapy Systems & Applicators Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: Tumor Ablation & Histotripsy Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: Interventional Oncology & Embolization Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: Tumor Treating Fields & Oncology-Specific Robotic/Surgical Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Cancer Treatment Devices Market: Treatment Modality Snapshot, 2025
TABLE 50: Segment Dashboard; Definition and Scope, by Treatment Modality
TABLE 51: U.S. Cancer Treatment Devices Market, by Treatment Modality, 2021–2035 (US$ Billion)
TABLE 52: U.S. Cancer Treatment Devices Market: Segment Share Analysis, by Treatment Modality, 2025 & 2035 (%)
TABLE 53: Radiation-Based Local Treatment Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Thermal Tumor Ablation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: Cryoablation & Non-Thermal Tissue Destruction Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: Catheter-Based Locoregional Treatment Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: Surgical, Robotic & Field-Based Treatment Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Cancer Treatment Devices Market: Cancer Type Snapshot, 2025
TABLE 59: Segment Dashboard; Definition and Scope, by Cancer Type
TABLE 60: U.S. Cancer Treatment Devices Market, by Cancer Type, 2021–2035 (US$ Billion)
TABLE 61: U.S. Cancer Treatment Devices Market: Segment Share Analysis, by Cancer Type, 2025 & 2035 (%)
TABLE 62: Breast Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Prostate Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: Lung Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: Colorectal Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: Liver Cancer and Hepatic Metastases Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: Pancreatic Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: Brain & Central Nervous System Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Other Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Cancer Treatment Devices Market: End User Snapshot, 2025
TABLE 71: Segment Dashboard; Definition and Scope, by End User
TABLE 72: U.S. Cancer Treatment Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 73: U.S. Cancer Treatment Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 74: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: Comprehensive and Specialty Cancer Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: Freestanding Radiation Oncology Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: Ambulatory Surgery & Interventional Oncology Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: Academic & Research Medical Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. Cancer Treatment Devices Market: Regional Snapshot, 2025
TABLE 80: Segment Dashboard; Definition and Scope, by Geography
TABLE 81: U.S. Cancer Treatment Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 82: U.S. Cancer Treatment Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 83: U.S. Cancer Treatment Devices Market: Regional Cancer Incidence and Treatment Population Analysis
TABLE 84: U.S. Cancer Treatment Devices Market: Regional Oncology Infrastructure and Procedure Volume Analysis
TABLE 85: West Region U.S. Cancer Treatment Devices Market: Regional Overview and Trends
TABLE 86: West Region U.S. Cancer Treatment Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 87: West Region U.S. Cancer Treatment Devices Market, by Product Category and Treatment Modality, 2021–2035 (US$ Billion)
TABLE 88: California Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: Washington Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: Arizona Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: Colorado Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: Oregon Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: Utah Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: Nevada Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: New Mexico Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Idaho Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Montana Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Wyoming Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Alaska Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Hawaii Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Northeast Region U.S. Cancer Treatment Devices Market: Regional Overview and Trends
TABLE 102: Northeast Region U.S. Cancer Treatment Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 103: Northeast Region U.S. Cancer Treatment Devices Market, by Product Category and Treatment Modality, 2021–2035 (US$ Billion)
TABLE 104: New York Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Massachusetts Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: New Jersey Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Pennsylvania Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Connecticut Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Maine Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Vermont Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: New Hampshire Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Rhode Island Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Delaware Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: South Region U.S. Cancer Treatment Devices Market: Regional Overview and Trends
TABLE 115: South Region U.S. Cancer Treatment Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 116: South Region U.S. Cancer Treatment Devices Market, by Product Category and Treatment Modality, 2021–2035 (US$ Billion)
TABLE 117: Texas Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Florida Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Georgia Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: North Carolina Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Tennessee Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: South Carolina Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Alabama Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Mississippi Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Louisiana Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Arkansas Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Kentucky Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Oklahoma Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Virginia Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Maryland Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: West Virginia Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Midwest Region U.S. Cancer Treatment Devices Market: Regional Overview and Trends
TABLE 133: Midwest Region U.S. Cancer Treatment Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 134: Midwest Region U.S. Cancer Treatment Devices Market, by Product Category and Treatment Modality, 2021–2035 (US$ Billion)
TABLE 135: Illinois Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Ohio Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Michigan Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Minnesota Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Indiana Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Wisconsin Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Missouri Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Iowa Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Kansas Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Nebraska Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: North Dakota Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: South Dakota Cancer Treatment Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: U.S. Cancer Treatment Devices Market: Competitive Landscape Snapshot, 2025
TABLE 148: U.S. Cancer Treatment Devices Market: Key Company Market Share Analysis, 2025
TABLE 149: U.S. Cancer Treatment Devices Market: Competitive Benchmarking by Product Category
TABLE 150: U.S. Cancer Treatment Devices Market: Competitive Benchmarking by Treatment Modality
TABLE 151: U.S. Cancer Treatment Devices Market: Company Positioning Matrix
TABLE 152: U.S. Cancer Treatment Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 153: Siemens Healthineers / Varian: Company Profile
TABLE 154: Elekta AB: Company Profile
TABLE 155: Accuray Incorporated: Company Profile
TABLE 156: Ion Beam Applications SA: Company Profile
TABLE 157: Mevion Medical Systems: Company Profile
TABLE 158: RefleXion Medical: Company Profile
TABLE 159: ZAP Surgical Systems: Company Profile
TABLE 160: Novocure: Company Profile
TABLE 161: HistoSonics: Company Profile
TABLE 162: Intuitive Surgical: Company Profile
TABLE 163: Johnson & Johnson MedTech: Company Profile
TABLE 164: Medtronic: Company Profile
TABLE 165: Boston Scientific Corporation: Company Profile
TABLE 166: AngioDynamics: Company Profile
TABLE 167: Stryker Corporation: Company Profile
TABLE 168: Terumo Interventional Systems: Company Profile
TABLE 169: Merit Medical Systems: Company Profile
TABLE 170: Profound Medical: Company Profile
TABLE 171: EDAP TMS: Company Profile
TABLE 172: GT Medical Technologies: Company Profile
TABLE 173: Theragenics Corporation: Company Profile
TABLE 174: Brainlab: Company Profile
TABLE 175: RaySearch Laboratories: Company Profile
TABLE 176: C-RAD: Company Profile
TABLE 177: Eckert & Ziegler BEBIG: Company Profile
TABLE 178: U.S. Cancer Treatment Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 179: U.S. Cancer Treatment Devices Market: Disruptive Technologies Impact Matrix
TABLE 180: U.S. Cancer Treatment Devices Market: Oncology Capital Equipment Replacement Outlook
TABLE 181: U.S. Cancer Treatment Devices Market: Future Site-of-Care Migration Analysis
TABLE 182: U.S. Cancer Treatment Devices Market: Emerging Business Models
TABLE 183: U.S. Cancer Treatment Devices Market: Recurring Consumables and Software Revenue Opportunities
TABLE 184: U.S. Cancer Treatment Devices Market: Investment Prioritization Matrix
TABLE 185: U.S. Cancer Treatment Devices Market: Technology Commercialization Risk Matrix
TABLE 186: U.S. Cancer Treatment Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 187: U.S. Cancer Treatment Devices Market: Strategic Recommendations for Radiation Oncology Equipment Companies
TABLE 188: U.S. Cancer Treatment Devices Market: Strategic Recommendations for Hospitals and Cancer Centers
TABLE 189: U.S. Cancer Treatment Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 190: U.S. Cancer Treatment Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 191: U.S. Cancer Treatment Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 192: U.S. Cancer Treatment Devices Market: Go-to-Market Strategy Considerations
TABLE 193: U.S. Cancer Treatment Devices Market: FDA and Reimbursement Commercialization Strategy
TABLE 194: U.S. Cancer Treatment Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 195: U.S. Cancer Treatment Devices Market: Regional and State-Level Commercial Prioritization
TABLE 196: U.S. Cancer Treatment Devices Market: Partnership, Licensing and M&A Opportunity Framework
TABLE 197: U.S. Cancer Treatment Devices Market: Scope Limitation
TABLE 198: U.S. Cancer Treatment Devices Market: Market Definition and Inclusion Limitation
TABLE 199: U.S. Cancer Treatment Devices Market: Data Use Limitation
TABLE 200: U.S. Cancer Treatment Devices Market: Forecasting Limitation
TABLE 201: U.S. Cancer Treatment Devices Market: Regulatory and Reimbursement Information Limitation
TABLE 202: U.S. Cancer Treatment Devices Market: Legal Disclaimer
TABLE 203: U.S. Cancer Treatment Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Cancer Treatment Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Cancer Treatment Devices Market Ecosystem
FIGURE 4: U.S. Cancer Treatment Devices Market Stakeholder Framework
FIGURE 5: U.S. Cancer Treatment Devices Market Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. Cancer Treatment Devices Market Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. Cancer Treatment Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 8: U.S. Cancer Treatment Devices Market Attractiveness Analysis
FIGURE 9: U.S. Cancer Treatment Devices Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Radiation Oncology Treatment-Room Utilization Framework
FIGURE 13: Hospital Capital Procurement Decision Framework
FIGURE 14: Oncology Site-of-Care Migration Framework
FIGURE 15: PESTEL Analysis
FIGURE 16: Porter’s Five Forces Analysis
FIGURE 17: Value Chain Analysis
FIGURE 18: Supply Chain Analysis
FIGURE 19: Oncology Capital Equipment Replacement-Cycle Framework
FIGURE 20: AI and Digital Oncology Impact Framework
FIGURE 21: FDA Regulatory and CMS Reimbursement Landscape
FIGURE 22: Total Cost of Ownership Framework for Cancer Treatment Equipment
FIGURE 23: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 24: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: External Beam Radiation Therapy, Radiosurgery & Particle Therapy Systems Market Trend, 2021–2035
FIGURE 26: Brachytherapy Systems & Applicators Market Trend, 2021–2035
FIGURE 27: Tumor Ablation & Histotripsy Devices Market Trend, 2021–2035
FIGURE 28: Interventional Oncology & Embolization Devices Market Trend, 2021–2035
FIGURE 29: Tumor Treating Fields & Oncology-Specific Robotic/Surgical Platforms Market Trend, 2021–2035
FIGURE 30: Treatment Modality Segment Market Share Analysis, 2025 & 2035
FIGURE 31: Treatment Modality Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 32: Radiation-Based Local Treatment Market Trend, 2021–2035
FIGURE 33: Thermal Tumor Ablation Market Trend, 2021–2035
FIGURE 34: Cryoablation & Non-Thermal Tissue Destruction Market Trend, 2021–2035
FIGURE 35: Catheter-Based Locoregional Treatment Market Trend, 2021–2035
FIGURE 36: Surgical, Robotic & Field-Based Treatment Market Trend, 2021–2035
FIGURE 37: Cancer Type Segment Market Share Analysis, 2025 & 2035
FIGURE 38: Cancer Type Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 39: Breast Cancer Treatment Devices Market Trend, 2021–2035
FIGURE 40: Prostate Cancer Treatment Devices Market Trend, 2021–2035
FIGURE 41: Lung Cancer Treatment Devices Market Trend, 2021–2035
FIGURE 42: Colorectal Cancer Treatment Devices Market Trend, 2021–2035
FIGURE 43: Liver Cancer and Hepatic Metastases Treatment Devices Market Trend, 2021–2035
FIGURE 44: Pancreatic Cancer Treatment Devices Market Trend, 2021–2035
FIGURE 45: Brain & CNS Cancer Treatment Devices Market Trend, 2021–2035
FIGURE 46: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 47: End User Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 48: Hospitals and Integrated Health Systems Market Trend, 2021–2035
FIGURE 49: Comprehensive and Specialty Cancer Centers Market Trend, 2021–2035
FIGURE 50: Freestanding Radiation Oncology Centers Market Trend, 2021–2035
FIGURE 51: Ambulatory Surgery & Interventional Oncology Centers Market Trend, 2021–2035
FIGURE 52: Academic & Research Medical Centers Market Trend, 2021–2035
FIGURE 53: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 54: Regional Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Regional Cancer Incidence and Oncology Infrastructure Comparison
FIGURE 56: West Region U.S. Cancer Treatment Devices Market Share Analysis, 2025
FIGURE 57: West Region Market Share Analysis by State, 2025
FIGURE 58: West Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 59: California Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 60: Washington Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 61: Arizona Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 62: Colorado Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 63: Oregon Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 64: Utah Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 65: Nevada Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 66: New Mexico Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 67: Idaho Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 68: Montana Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 69: Wyoming Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 70: Alaska Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 71: Hawaii Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 72: Northeast Region U.S. Cancer Treatment Devices Market Share Analysis, 2025
FIGURE 73: Northeast Region Market Share Analysis by State, 2025
FIGURE 74: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 75: New York Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 76: Massachusetts Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 77: New Jersey Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 78: Pennsylvania Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 79: Connecticut Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 80: Maine Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 81: Vermont Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 82: New Hampshire Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 83: Rhode Island Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 84: Delaware Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 85: South Region U.S. Cancer Treatment Devices Market Share Analysis, 2025
FIGURE 86: South Region Market Share Analysis by State, 2025
FIGURE 87: South Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 88: Texas Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 89: Florida Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 90: Georgia Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 91: North Carolina Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 92: Tennessee Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 93: South Carolina Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 94: Alabama Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 95: Mississippi Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 96: Louisiana Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 97: Arkansas Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 98: Kentucky Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 99: Oklahoma Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 100: Virginia Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 101: Maryland Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 102: West Virginia Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 103: Midwest Region U.S. Cancer Treatment Devices Market Share Analysis, 2025
FIGURE 104: Midwest Region Market Share Analysis by State, 2025
FIGURE 105: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 106: Illinois Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 107: Ohio Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 108: Michigan Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 109: Minnesota Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 110: Indiana Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 111: Wisconsin Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 112: Missouri Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 113: Iowa Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 114: Kansas Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 115: Nebraska Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 116: North Dakota Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 117: South Dakota Cancer Treatment Devices Market Size and Trend Analysis, 2021–2035
FIGURE 118: U.S. Cancer Treatment Devices Market: Competitive Landscape and Key Company Market Share, 2025
FIGURE 119: Company Positioning Matrix
FIGURE 120: Key Player Product Portfolio Benchmarking
FIGURE 121: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 122: U.S. Cancer Treatment Devices Innovation Roadmap
FIGURE 123: Adaptive Radiation Therapy Adoption Roadmap
FIGURE 124: Histotripsy and Non-Thermal Tumor Destruction Opportunity Map
FIGURE 125: Tumor Treating Fields Expansion Roadmap
FIGURE 126: Proton and Particle Therapy Technology Roadmap
FIGURE 127: Future Market Scenario Analysis, 2026–2035
FIGURE 128: Disruptive Technologies Impact Matrix
FIGURE 129: Oncology Capital Equipment Replacement Outlook
FIGURE 130: Future Site-of-Care Migration Framework
FIGURE 131: Emerging Business Models Matrix
FIGURE 132: Investment Prioritization Matrix
FIGURE 133: Technology Commercialization Risk Matrix
FIGURE 134: Strategic Growth Roadmap for U.S. Cancer Treatment Device Companies
FIGURE 135: Go-to-Market Strategy Framework
FIGURE 136: FDA and Reimbursement Commercialization Framework
FIGURE 137: Product Positioning and Portfolio Expansion Framework
FIGURE 138: Regional and State-Level Commercial Prioritization Map
FIGURE 139: Partnership, Licensing and M&A Opportunity Framework
FIGURE 140: Report Scope and Disclaimer Framework